Upgrade to SI Premium - Free Trial

JPMorgan Reinstates Ascendis Pharma (ASND) at Overweight

May 20, 2026 4:30 AM
JPMorgan analyst Jessica Fye reinstates coverage on Ascendis Pharma (NASDAQ: ASND) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

New Coverage